Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene profiling changes in mouse bone marrow derived macrophages upon SUMOylation inhibition

ABSTRACT: SUMOylation, a posttranslational modification, regulates protein function by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a lysine (Lys) residue on target proteins. Here we use ML-792, a selective SUMO-activating enzyme (SAE) inhibitor, to inhibit global SUMOylation in macrophages derived from bone marrow of C57BL/6 mice. Mouse bone marrow cells isolated from 6–10 weeks C57BL/6 mice were cultured in IMDM medium supplemented with 10% (vol/vol) FBS and 10 ng/mL of macrophage colony-stimulating factor (M-CSF). After 6–8 days of differentiation, the cells were treated with vehicle or ML-792 at 0.5 μM for 24 h. Total RNA was purified using miRNeasy RNA isolation kit (Qiagen) then Ribo-Zero RNA-seq was performed.

ORGANISM(S): Mus musculus

PROVIDER: GSE217604 | GEO | 2023/10/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Probing the Roles of SUMOylation in Cancer Cell Biology Using a Selective SAE inhibitor

Project description:Small ubiquitin-like modifier (SUMO) family proteins regulate target protein functions by post-translational modification. However, a potent and selective inhibitor to target the SUMO pathway has been lacking. Here we describe ML-792, the first mechanism-based SUMO-activating enzyme (SAE) inhibitor with nanomolar potency in cellular assays. ML-792 selectively blocks SAE enzyme activity and total SUMOylation, which leads to reduced cancer cell proliferation. Moreover, induction of the MYC oncogene increased the ML-792 mediated viability effect in cancer cells, indicating potential application of SAE inhibitors in MYC-amplified tumors. Using ML-792, we further explored the critical roles of SUMOylation in mitotic progression and chromosome segregation. Furthermore, expression of an SAE catalytic subunit (UBA2) mutant S95N/M97T rescued SUMOylation loss and the mitotic defect induced by ML-792, confirming the selectivity of ML-792. As a potent and selective SAE inhibitor, ML-792 provides rapid loss of endogenously SUMOylated proteins allowing for novel insights into SUMO biology.

2017-09-01 | GSE100408 | GEO

SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

Project description:SUMOylation, a posttranslational modification, regulates proteins by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a lysine (Lys) residue on target proteins. Here we use TAK-981, a selective SUMO-activating enzyme (SAE) inhibitor, to inhibit global SUMOylation in glucocorticoid sensitive and resistant multiple myeloma cell lines.

2021-12-31 | GSE163682 | GEO

SUMOylation controls Daunorubicin-regulated gene expression in the Acute Myeloid Leukemia cell line HL-60

Project description:SUMOylation, a post-translational modification of the ubiquitin family plays key roles in Acute Myeloid Leukemias response to therapies, in particular through the regulation of gene expression. We have investigated here how inhibition of SUMOylation with ML-792 affects gene daunorubicine (DNR-)-regulated gene expression. We found that inhibition of SUMOylation limits DNR-induce up- or down-regulation of gene expression.

2023-06-23 | GSE198982 | GEO

SUMOylation regulates the protein network and chromatin accessibility at glucocorticoid receptor-binding sites [sequencing]

Project description:Glucocorticoid receptor (GR) is an essential transcription factor (TF), controlling metabolism, development and immune responses. SUMOylation regulates chromatin occupancy and target gene expression of GR in a locus-selective manner, but the mechanism of regulation has remained elusive. Here, we identify the protein network around chromatin-bound GR by using selective isolation of chromatin-associated proteins and show that the network is affected by receptor SUMOylation, with several nuclear receptor coregulators and chromatin modifiers preferring interaction with SUMOylation-deficient GR and proteins implicated in transcriptional repression preferring interaction with SUMOylation-competent GR. This difference is reflected in our chromatin binding, chromatin accessibility and gene expression data, showing that the SUMOylation-deficient GR is more potent in binding and opening chromatin at glucocorticoid-regulated enhancers and inducing expression of target loci. Blockage of SUMOylation by a SUMO-activating enzyme inhibitor (ML-792) phenocopied to a large extent the consequences of GR SUMOylation deficiency on chromatin binding and target gene expression. Our results thus show that SUMOylation modulates the specificity of GR by regulating its chromatin protein network and accessibility at GR-bound enhancers. We speculate that many other SUMOylated TFs utilize a similar regulatory mechanism.

2021-01-08 | GSE64301 | GEO

SUMOylation regulates the protein network and chromatin accessibility at glucocorticoid receptor-binding sites [array]

2021-01-08 | GSE64372 | GEO

Pharmacologic targeting of SUMOylation drives mitochondrial dysfunction and metabolic alterations in B cell Malignancies

Project description:Sumoylation is a post-translational modification process that is deregulated in cancer. We foundthat sumoylation machinery was overexpressed in diffuse large B-cell lymphoma (DLBCL).Treatment with TAK-981, a SUMO-activating enzyme (SAE) inhibitor, induced desumoylationof cytoplasmic and mitochondrial proteins, restricting growth of DLBCL and mantle celllymphoma (MCL) cell lines and primary cells. DLBCL cells treated with TAK-981 exhibitedDNA damage, G2 arrest and downregulation of DNA repair, MYC and OxPhos pathways. SAEinhibition disrupted mitochondrial integrity and function, accompanied by mitophagy and rapidaccumulation of ROS. Metabolomic profiling revealed decreases in Krebs cycle substrates, andSeahorse respirometry confirmed dramatic reduction in OxPhos upon SAE inhibition. CRISPR-Cas9 loss-of-function library screens implicated NFκB, TP53, DNA damage andcentromere/telomere gene pathways in resistance to SAE inhibition; knockout of TP53 or BAXrescued DLBCL cells from TAK-981-induced apoptosis. Treatment with TAK-981 prolongedsurvival of mice xenografted with DLBCL and MCL PDX tumors. Thus, sumoylation is apromising target in lymphoid malignancies.

2024-02-02 | GSE254913 | GEO

SLAM-seq ML-792

Project description:SLAM-seq ML-792

| PRJNA703953 | ENA

Gene expression profiles in wild-type and SUMO knockdown mice after forebrain ischemia

Project description:Transient brain ischemia massively activates global SUMOylation. A large fraction of SUMO targets are nuclear proteins involved in gene expression. However, gene expression profile modulated by ischemia-induced SUMOylation has not been studied. Using a SUMO knockdown (SUMO-KD) mouse model and microarray technique, we investigated how SUMOylation modulated gene expression after brain ischemia. Wild-type and SUMO-KD mice were subjected to transient forebrain ischemia or sham surgery. The hippocampal CA1 subfield samples collected at 3 hours reperfusion were analyzed using Affymetrix microarrays.

2016-08-01 | E-GEOD-80681 | biostudies-arrayexpress

Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of androgen receptor in prostate cancer cells (LNCaP RNA-seq)

Project description:The androgen receptor (AR) is pivotal in prostate cancer (PCa) progression and represents a critical therapeutic target. AR-mediated gene regulation involves intricate interactions with nuclear proteins, with many mediating and undergoing post-translational modifications that present alternative therapeutic avenues. Through chromatin proteomics in PCa cells, we identified SUMO ligases together with nuclear receptor coregulators and pioneer transcription factors within the AR’s protein interaction network. Intriguingly, this network displayed a significant association with SUMO2/3. To elucidate the influence of SUMOylation on AR chromatin interactions and subsequent gene regulation, we inhibited SUMOylation using ML-792 (SUMOi). While androgens generally facilitated the co-occupancy of SUMO2/3 and AR on chromatin, SUMOi induced divergent effects dependent on the enhancer type. SUMOi augmented AR’s pioneer-like binding on inaccessible chromatin regions abundant in androgen response elements (AREs) and diminished its interaction with accessible chromatin regions sparse in AREs yet rich in pioneer transcription factor motifs. The SUMOi-impacted AR-binding sites divergently influenced AR-regulated genes; those associated with AR-mediated activation played roles in negative regulation of cell proliferation, while those with AR-mediated repression were involved in pattern formation. In conclusion, our findings underscore the pervasive influence of SUMOylation in shaping AR's role in PCa cells, potentially unveiling new therapeutic strategies.

2024-07-09 | GSE216549 | GEO

Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of androgen receptor in prostate cancer cells (RNA-seq)

2024-07-09 | GSE211159 | GEO